NEW YORK (360Dx) – Quanterix said after the close of the market on Monday that it is collaborating with OncoGenesis to develop a test for cervical disease.

The companies will develop the protein biomarker-based test using Quanterix's forthcoming SP-X Imaging and Analysis system, and OncoGenesis will handle test commercialization. Called CerMark, the test will measure protein markers linked to high-risk HPV infection and cervical disease progression.